Capital Management – Talk Bio

Actionable Insights Powered by AI

Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders

2 months ago talkbio0Tagged Antibodies, Bispecific, Bambusa Therapeutics, Capital Management, Funding, Immunology, Inflammation, Rheumatoid Arthritis, Series

Bambusa Therapeutics, bispecific antibodies, immunology, inflammation, Series A funding, RA Capital Management, I&I disorders

Masimo Appoints Michelle Brennan as Interim CEO Following Joe Kiani’s Resignation

7 months ago talkbio0Tagged board of directors, Brennan, Capital Management, CEO, Kiani, Masimo, Michelle, Politan, resignation

Masimo, Joe Kiani, Michelle Brennan, Politan Capital Management, Interim CEO, Board of Directors, Resignation

Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody

8 months ago talkbio0Tagged Antibodies, Bispecific, Autoimmune Diseases, Capital Management, Forbion, Funding, Navigator Medicines, Rheumatoid Arthritis, Series

Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion

Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market

9 months ago talkbio0Tagged Administration occupational activities, Ascenta Capital, biotech, Blue color, Capital, Capital Management, Cardiovascular system, Cardurion, Farallon, fidelity, Genus: Digitalis, Granulovirus, Healthcare Opportunities, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Invus, Millennium, NEA, Research Company, Series B

Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures